# OnCo record raised-liver-enzymes-on-targeted-anticancer-drugs (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/raised-liver-enzymes-on-targeted-anticancer-drugs/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "raised-liver-enzymes-on-targeted-anticancer-drugs" ;
  schema:name "Raised liver enzymes on targeted anticancer drugs: monitoring, hold and stop rules"@en ;
  schema:alternateName "drug-induced liver injury on cancer drugs"@en, "DILI on kinase inhibitors"@en, "raised ALT on targeted therapy"@en, "raised AST on targeted therapy"@en, "transaminitis on TKIs"@en, "hepatotoxicity monitoring"@en, "liver function tests on CDK4/6 inhibitors"@en, "Hy's law"@en ;
  schema:description "Many cancer tablets and some infusions can irritate the liver, sometimes with no symptoms, so liver blood tests are taken before treatment and at set intervals after. A mild rise is watched, a larger one means a pause and often a lower dose, and a rise with jaundice usually means stopping. Yellow skin or eyes, dark urine or itching need a call to your cancer team straight away."@en ;
  schema:url <https://onco.cc/protocols/raised-liver-enzymes-on-targeted-anticancer-drugs/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  onco:related <https://onco.cc/protocols/irae-hepatitis/>, <https://onco.cc/protocols/hepatic-dose-adjustment-of-anticancer-drugs/>, <https://onco.cc/protocols/hepatic-veno-occlusive-disease-after-transplant/> ;
  onco:drugs <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/tucatinib/>, <https://onco.cc/drugs/lapatinib/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/vorasidenib/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/trabectedin/>, <https://onco.cc/drugs/gilteritinib/>, <https://onco.cc/drugs/olutasidenib/>, <https://onco.cc/drugs/enasidenib/>, <https://onco.cc/drugs/zynlonta/> ;
  onco:terms <https://onco.cc/terms/hepatotoxicity/>, <https://onco.cc/terms/ctcae-grading/> .
